FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1172-1174 October 16, 1997 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Fisher, R. I. Related Article by Kaplan, L. D. PubMed Citation

To the Editor: Kaplan et al. (June 5 issue)¹ "recommend that low-dose chemotherapy be considered for most patients with HIV [human immunodeficiency virus] infection and non-Hodgkin's lymphoma," but their results do not convincingly support a general recommendation to use low-dose chemotherapy in patients with high CD4+ counts. Higher CD4+ counts are associated with significantly more complete responses and longer median survival, but in this trial, patients were not stratified according to CD4+ count.² Although the authors controlled for the absolute CD4+ count in the analysis of survival, the primary end point, and found no difference between the treatment groups, the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Jick, H., Vasilakis, C., Weinrauch, L. A., Meier, C. R., Jick, S. S., Derby, L. E. (1998). A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation. NEJM 339: 719-724 [Abstract] [Full Text]